Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5740-5742

  Babalik, Aylin ^a   Ulus, Ismail Hakki ^b   Bakirci, Nadi ^b   Kuyucu, Tulin ^a   Arpag, Huseyin ^a   Dagyildizi, Lale ^a   Capaner, Esen ^c  

^a Sureyyapasa Chest Diseases   (Turkey)

^b ACIBADEM UNIVERSITY   (Turkey)

^c Kaan Med Toxicology Laboratory   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SHORT COURSE THERAPY;

ADULT; ANTITUBERCULAR AGENTS; BIOLOGICAL AVAILABILITY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; ETHAMBUTOL; FEMALE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 84885910818     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01345-13     Document Type: Article

References (21)

1. Kim SH, Hong YP, Lew WJ, Yang SC, Lee EG. 1995. Incidence of pulmonary tuberculosis among diabetics. Tuber. Lung Dis. 76:529-533.
2. Pablos-Méndez A, Blustein J, Knirsch CA. 1997. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am. J. Public Health 87:574-579.
3. Alisjahbana B, van Crevel R, Sahiratmadja E, den Heijer M, Maya A, Istriana E, Danusantoso H, Ottenhoff THM, Nelwan RHN, van der Meer JWM. 2006. Diabetes mellitus is strongly associated with tuberculosis in Indonesia. Int. J. Tuberc. Lung Dis. 10:696-700.
4. Stevenson CR, Forouhi NG, Roglic G, Williams BG, Laurer JA, Dye C, Unwin N. 2007. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health 7:234.
5. Dobler CC, Flack JR, Marks GB. 2012. Risk of tuberculosis among people with diabetes mellitus: an Australian nationwide cohort study. BMJ Open 2:e000666.
6. Singla R, Khan N, Al-Sharif N, Al-Sayegh MO, Shaikh MA, Osman MM. 2006. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. Int. J. Tuberc. Lung Dis. 10:74-79.
7. Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff THM, Nelwan RHH, Parwati I, van der Meer JWM, van Crevel R. 2007. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin. Infect. Dis. 45: 428-435.
8. Fisher-Hoch SP, Whitney E, McCormick JB, Crespo G, Smith B, Rahbar MH, Restrepo BI. 2008. Type 2 diabetes and multi-drug resistant tuberculosis. Scand. J. Infect. Dis. 40:888-893.
9. Wang CS, Yang HC, Chen HC, Chuang SH, Chong IW, Hwang JJ, Huang MS. 2009. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol. Infect. 137:203-210.
10. Chang J-T, Dou H-Y, Yen C-L, Wu Y-H, Huang R-M, Lin H-J, Su I-J, Shieh C-C. 2011. Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance. J. Formos. Med. Assoc. 110:372-381.
11. Heysell SK, Moore JL, Keller SJ, Houpt ER. 2010. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg. Infect. Dis. 16:1546-1553.
12. Nijland HMJ, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RHH, van der Ven AJAM, Danusantoso H, Aarnoutse RE, van Crevel R. 2006. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin. Infect. Dis. 43:848-854.
13. Ruslami R, Nijland HMJ, Adhiarta IGN, Kariadi AHKS, Alisjahbana B, Aarnoutse RE, van Crevel R. 2010. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob. Agents Chemother. 54:1068-1074.
14. Requena-Méndez A, Davies G, Ardrey A, Jave O, Lopez-Romero SL, Ward SA, Moore DAJ. 2012. Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. Antimicrob. Agents Chemother. 56:2357-2363.
15. Unsalan S, Sancar M, Bekce B, Clark PM, Karagoz T, Izzettin FV, Rollas S. 2005. Therapeutics monitoring isoniazid, pyrazinamide and rifampicin in tuberculosis patients using LC. Chromatographia 61:505-598.
16. Chenevier P, Massias L, Geylard D, Farinotti R. 1998. Determination of ethambutol in plasma by high-performance liquid chromatography after pre-column derivatization. J. Chromatogr. B Biomed. Sci. Appl. 708:310-315.
17. Peloquin CA. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169-2183.
18. Dostalek M, Akhlaghi F, Puzanovova M. 2012. Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin. Pharmacokinet. 51:481-499.
19. Jindani A, Aber VR, Edwards EA, Mitchison DA. 1980. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 121:939-949.
20. Donald PR, Sirgel FA, Botha FJ, Seifart HI, Parkin DP, Vandenplas ML, Van de Wal BW, Maritz JS, Mitchison DA. 1997. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 156(Pt 1):895-900.
21. Babalik A, Mannix S, Francis D, Menzies D. 2011. Therapeutic drug monitoring in the treatment of active tuberculosis. Can. Respir. J. 18:225-229.